The Company is strengthening its new product vaccine pipeline by developing new vaccines like Classical Swine Fever (CSF), Sheep Pox and an improved version of Brucella vaccines.

The company's gross margins of the vaccines and the health products have been in line with the corresponding quarter.

Hester Biosciences Limited has reported consolidated net profit of Rs. 3.56 crore and Revenue from Operations of Rs. 50.70 crore for the Q1FY23. 

The company's gross margins of the vaccines and the health products have been in line with the corresponding quarter.

However, the overall margins have reduced due to the increase in the proportion of health products sales which have lower gross margins compared to vaccines. 

Health Products sales constituted 34% of the total sales in Q1 FY23, versus 20% in Q1 FY22.

The Company is strengthening its new product vaccine pipeline by developing new vaccines like Classical Swine Fever (CSF), Sheep Pox and an improved version of Brucella vaccines.